Oxford, UK – 11 March 2019: Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a leading gene and cell therapy group, notes Axovant’s update on the Phase 2 SUNRISE-PD study of AXO-Lenti-PD.
Axovant reported 3-month data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease. The cohort consisted of two patients with advanced Parkinson’s disease who received a one-time administration of the lowest dose of AXO-Lenti-PD.
Based on initial feedback received from members of the Data Monitoring Committee (DMC), Axovant plans to proceed to the second dose cohort of AXO-Lenti-PD. The first subject in this second cohort is expected to be dosed in the second quarter of 2019.
Oxford Biomedica entered into an exclusive worldwide licensing agreement with Axovant Sciences (now Axovant Gene Therapies) in June 2018 to develop and commercialise AXO-Lenti-PD (previously OXB-102) for Parkinson’s disease, worth up to $842.5 million in upfront, development, sales and regulatory milestones, with tiered royalty payments.
To view today’s release from Axovant, follow this link.
Oxford Biomedica plc
John Dawson, Chief Executive Officer
T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer
T: +44 (0)1865 783 000
Catherine Isted, Head of Corporate Development & IR
T: +44 (0)1865 954 161 / E: firstname.lastname@example.org
Sarah MacLeod, Head of Communications
T: +44 (0)7747 602 739 / E: email@example.com
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
T: +44 (0)20 3709 5700
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com